AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06247345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADEL-Y01 - healty participants
Description: In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
Study NCT06247345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Healthy Participants
Description: In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
Study NCT06247345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADEL-Y01 - MCI/AD
Description: In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy.
Study NCT06247345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - MCI/AD
Description: In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions.
Study NCT06169319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Biologic: Intrafascial injection
Study NCT06169319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intrafascial injection
Study NCT04074096 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotaxic radiosurgery (SRS)
Description: For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm).
Study NCT04074096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Oral Tablet
Description: All patients: binimetinib 45 mg PO BID.
Study NCT04074096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib Oral Capsule
Description: All patients: encorafenib 450 mg PO QD
Study NCT04074096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All patients: pembrolizumab 200 mg IV Q3W
Study NCT05605925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/lumefantrine
Description: 4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
Study NCT05605925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: 4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
Study NCT05605925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: IVN 600 mcg/kg/day for 3 days
Study NCT05490381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: Given via injection
Study NCT05490381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiogram
Description: Undergo diagnostic cerebral angiogram
Study NCT05490381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Embolization
Description: Undergo tumor vessel embolization
Study NCT05490381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyvinyl Alcohol
Description: Given via catheter
Study NCT05490381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethiodized Oil
Description: Given via catheter
Study NCT05490381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo head and neck CT scans
Study NCT05490381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chart Abstraction
Description: Ancillary studies
Study NCT05465967 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Quadratus lumborum Block
Description: 1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
Study NCT05465967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum Block
Description: 1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
Study NCT05129111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL VIBRATION OF THE PAROTID GLANDS
Description: The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
Study NCT05129111 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PHYSICAL VIBRATION OF THE PAROTID GLANDS
Description: The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
Study NCT06030154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy
Study NCT06030154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity Therapy
Description: Amplification of Positivity Therapy
Study NCT06030154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys and Interviews
Description: Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
Study NCT06030154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys and Interviews
Description: Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
Study NCT04839185 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ferumoxytol infusion
Description: Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject.
Study NCT04839185 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI scan
Description: The MRI scanning procedure will last for approximately 60 minutes.
Study NCT05393544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally assisted peer recovery coach
Description: The certified peer recovery coach utilized an existing care coordination smartphone app to provide support to the patient during and after an inpatient detoxification treatment for alcohol use disorder. The coach utilized the telephone or text messages to send daily motivational messages, remind about upcoming appointments, and checked-in if responses were concerning. Follow-up by the coach continued for 30 days.
Study NCT05362825 — intervention group
Intervention type: DRUG
Intervention: Neo-adjuvant Chemotherapy FOLFOXIRI Regimen
Description: Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
Study NCT05362825 — intervention group
Intervention type: PROCEDURE
Intervention: synchronous resection surgery
Description: Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
Study NCT05070845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06835375
Description: CXCR5 inhibitor
Study NCT05448053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ilizarov
Description: Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
Study NCT06216769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours.
Study NCT06216769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours.
Study NCT06129006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydrodilatation with steroid in group A versus hyalase in group B
Description: Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution.
Study NCT06166251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low ıntensity aerobic exercise
Description: The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.
Study NCT06166251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate ıntensity aerobic exercise
Description: The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
Study NCT05746000 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Group (IG)
Description: Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
Study NCT05746000 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group (CG)
Description: Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
Study NCT06282302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group control
Description: Group control The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.
Study NCT06282302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Exercise
Description: The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.
Study NCT06282302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
Study NCT05371795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort Marker 2.0
Description: The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
Study NCT05371795 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lancets
Description: The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
Study NCT04752228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Philadelphia ACE Survey
Description: The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.
Study NCT04752228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Assessment
Description: The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
Study NCT04752228 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle Assessment
Description: The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
Study NCT05211973 — intervention group
Intervention type: DEVICE
Intervention: Wrist Actigraphy Device
Description: a watch like wearable sensor
Study NCT05211973 — intervention group
Intervention type: DEVICE
Intervention: Smart Body Weight Scale
Description: a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
Study NCT05211973 — intervention group
Intervention type: DEVICE
Intervention: Chair Scale
Description: a wheel-chair compatible scale to measure body weight
Study NCT05420077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 10 µg
Description: Low Dose
Study NCT05420077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 30 µg
Description: Mid Dose
Study NCT05420077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 60 µg
Description: High Dose
Study NCT05211973 — intervention group
Intervention type: DEVICE
Intervention: Handheld Body Fat Percentage Device
Description: a handheld device that measures body fat percentage
Study NCT05062798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standart bottle
Description: 1. After the surgery, standard bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made.
Study NCT05062798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Squeezable bottle
Description: 1. After the surgery, squeezable bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made.
Study NCT05205005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocalyx
Description: 3,712mg (six capsules) of DSGP for eight weeks.
Study NCT05205005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
Study NCT05211973 — intervention group
Intervention type: DEVICE
Intervention: Bioelectric Impedance Analysis Scale
Description: a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
Study NCT05571540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: U-CAR-T Cells (LstCAR019)
Description: LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one: 1×10\^6 cells/kg;Dose level two: 2×10\^6 cells/kg;Dose level three: 5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion.
Study NCT04994795 — intervention group
Intervention type: OTHER
Intervention: Predictive models (data collection)
Description: Machine learning predictive models
Study NCT06243809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg Oral Tablet
Description: Linagliptin 5 mg Oral Tablet
Study NCT06284460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Given by PO
Study NCT06284460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO
Study NCT04883099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism
Description: Contact Lenses for Presbyopia
Study NCT05885373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIM01
Description: SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
Study NCT05294497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette
Study NCT05294497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine
Study NCT05294497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine